CTNS Gene
Introduction
The CTNS gene (Cystinosin, Lysosomal Cystine Transporter) encodes a lysosomal membrane protein responsible for transporting cystine out of lysosomes. Mutations cause cystinosis, a lysosomal storage disorder with significant neurological manifestations.
Overview
flowchart TD
TMEM55B["TMEM55B"] -->|"regulates"| CTNS["CTNS"]
TMEM55B["TMEM55B"] -->|"associated with"| CTNS["CTNS"]
style CTNS fill:#4fc3f7,stroke:#333,color:#000
The CTNS gene is located on chromosome 17p13.2 and encodes cystinosin, a 367-amino acid integral lysosomal membrane protein that functions as a proton-driven cystine transporter<sup>[1]</sup>. Loss-of-function mutations in CTNS cause cystinosis, an autosomal recessive lysosomal storage disorder characterized by intralysosomal accumulation of the amino acid cystine throughout the body<sup>[2]</sup>. While cystinosis primarily affects the kidneys, the neurological complications — including progressive cerebral atrophy, cerebellar dysfunction, and neurocognitive impairment — place this gene at the intersection of lysosomal biology and neurodegeneration<sup>[3]</sup>. [@gahl2002]
<div class="infobox infobox-gene"> [@trauner2010]
...CTNS Gene
Introduction
The CTNS gene (Cystinosin, Lysosomal Cystine Transporter) encodes a lysosomal membrane protein responsible for transporting cystine out of lysosomes. Mutations cause cystinosis, a lysosomal storage disorder with significant neurological manifestations.
Overview
Mermaid diagram (expand to render)
The CTNS gene is located on chromosome 17p13.2 and encodes cystinosin, a 367-amino acid integral lysosomal membrane protein that functions as a proton-driven cystine transporter<sup>[1]</sup>. Loss-of-function mutations in CTNS cause cystinosis, an autosomal recessive lysosomal storage disorder characterized by intralysosomal accumulation of the amino acid cystine throughout the body<sup>[2]</sup>. While cystinosis primarily affects the kidneys, the neurological complications — including progressive cerebral atrophy, cerebellar dysfunction, and neurocognitive impairment — place this gene at the intersection of lysosomal biology and neurodegeneration<sup>[3]</sup>. [@gahl2002]
<div class="infobox infobox-gene"> [@trauner2010]
| | | [@kalatzis2001]
|---|---| [@ivanova2015]
| Gene Symbol | CTNS | [@festa2018]
| Full Name | Cystinosin, Lysosomal Cystine Transporter | [@ariceta2015]
| Chromosomal Location | 17p13.2 | [@syres2009]
| NCBI Gene ID | [1497](https://www.ncbi.nlm.nih.gov/gene/1497) |
| OMIM | [606272](https://omim.org/entry/606272) |
| Ensembl | [ENSG00000040531](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000040531) |
| UniProt | [O60931](https://www.uniprot.org/uniprot/O60931) |
| Associated Diseases | Cystinosis (infantile nephropathic, juvenile, ocular) |
</div>
Function
Lysosomal Cystine Transport
Cystinosin is a seven-transmembrane-domain protein localized to the lysosomal membrane. It functions as an H⁺-driven cystine symporter, coupling the efflux of cystine from the lysosomal lumen to proton import<sup>[1]</sup>:
- Cystine Export: Transports the disulfide amino acid cystine (oxidized form of cysteine) out of lysosomes
- Proton Coupling: Uses the lysosomal proton gradient (maintained by v-ATPase) as driving force
- Redox Balance: By exporting cystine for reduction to cysteine in the cytosol, supports cellular glutathione synthesis
- Lysosomal Homeostasis: Prevents cystine crystal accumulation that damages lysosomal membranes
Molecular Mechanism
The CTNS protein contains several functionally important features<sup>[4]</sup>:
- Seven transmembrane domains: Form the transport channel for cystine
- Lysosomal targeting motifs: GYDQL sequence in the C-terminal tail directs protein to lysosomes
- N-glycosylation sites: Seven N-linked glycosylation sites in the intralysosomal loops
- PQ-loop domains: Two conserved PQ-loop motifs essential for transport function
Broader Cellular Roles
Beyond cystine transport, CTNS has been implicated in<sup>[5]</sup>:
- [mTORC1](/mechanisms/mtor-signaling-neurodegeneration) signaling: Cystinosin interacts with v-ATPase and Ragulator complex, modulating mTORC1 recruitment to lysosomes
- [Autophagy](/mechanisms/autophagy-lysosomal-pathway-parkinsons): Loss of CTNS impairs autophagic flux and leads to accumulation of autophagosomes
- Vesicular Trafficking: Required for proper endolysosomal trafficking and lysosome biogenesis
- Chaperone-mediated [autophagy](/entities/autophagy) (CMA): CTNS loss disrupts LAMP2A-mediated CMA
Disease Associations
Cystinosis
Cystinosis is classified into three clinical forms based on age of onset and severity<sup>[2]</sup>:
| Form | Onset | Features | Frequency |
|------|-------|----------|-----------|
| Infantile nephropathic | 6-12 months | Renal Fanconi syndrome, growth failure, photophobia, progressive renal failure | ~95% of cases |
| Juvenile/adolescent | Late childhood | Milder renal disease, photophobia | ~5% of cases |
| Ocular (non-nephropathic) | Adulthood | Corneal cystine crystals, photophobia only | Rare |
Neurological Manifestations
With improved renal management and cysteamine therapy extending survival, neurological complications have become increasingly recognized<sup>[3]</sup>:
- Cerebral atrophy: Progressive cortical and subcortical volume loss on MRI
- Cerebellar dysfunction: Ataxia, dysarthria, and dysphagia appearing in the second-third decade
- Neurocognitive decline: Deficits in visual-spatial processing, executive function, and memory
- Myopathy: Progressive distal vacuolar myopathy with cystine crystal deposition
- Encephalopathy: Cystinosin-deficient [neurons](/entities/neurons) show increased oxidative stress and [apoptosis](/entities/apoptosis)
Relevance to Neurodegeneration
CTNS mutations illuminate fundamental principles of lysosomal dysfunction in neurodegeneration<sup>[6]</sup>:
- Lysosomal Storage: Parallels with [Niemann-Pick disease](/diseases/niemann-pick-disease), [Gaucher disease](/diseases/gaucher-disease), and other storage disorders
- Autophagy Impairment: Defective autophagy connects to [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) pathways
- [mTOR](/mechanisms/mtor-signaling-pathway) Dysregulation: mTORC1 hyperactivation in CTNS-deficient cells mirrors pathology seen in tauopathies
- Oxidative Stress: Cystine accumulation depletes glutathione, increasing vulnerability to [reactive oxygen species](/entities/reactive-oxygen-species)
Common Variants
| Variant | Effect | Phenotype |
|---------|--------|-----------|
| 57-kb deletion | Loss of exons 1-10 + upstream CARKL gene | Severe infantile nephropathic cystinosis; most common European allele (~50%) |
| c.18_21delGACT | Frameshift, premature stop | Infantile nephropathic cystinosis |
| c.681G>A (W227X) | Nonsense mutation | Infantile nephropathic cystinosis |
| c.1015G>A (G339R) | Missense in TM7 | Late-onset/juvenile cystinosis |
| c.329T>C (L110P) | Missense, partial function | Juvenile/intermediate cystinosis |
Therapeutic Implications
Cysteamine Therapy
[Cysteamine](/therapeutics/cysteamine) (Cystagon, Procysbi) is the only approved treatment for cystinosis<sup>[7]</sup>:
- Mechanism: Enters lysosomes and reacts with cystine to form cysteine-cysteamine mixed disulfide, which exits via the lysine transporter (PQLC2)
- Efficacy: Delays renal failure by 5-10 years but does not fully prevent neurological complications
- Limitations: Requires lifelong treatment, has side effects (GI upset, breath/body odor)
Emerging Therapies
- Gene therapy: AAV-mediated CTNS delivery shows promise in preclinical models<sup>[8]</sup>
- Hematopoietic stem cell transplantation: Cross-correction of cystinotic cells via tunneling nanotubes
- mTOR modulators: [Rapamycin](/therapeutics/rapamycin-tauopathy) and analogs to correct mTORC1 hyperactivation
- Chaperone therapies: Small molecules that stabilize partially functional cystinosin mutants
Expression
CTNS is ubiquitously expressed, with notable expression in<sup>[1]</sup>:
- Kidney: Proximal tubular epithelial cells (highest expression)
- Brain: Neurons and [astrocytes](/entities/astrocytes) throughout [cortex](/brain-regions/cortex), hippocampus, and cerebellum
- Retina: Retinal pigment epithelium and photoreceptors
- Thyroid: Follicular cells
- Liver: Hepatocytes
In the brain, expression is particularly high in regions vulnerable to cystine accumulation, including the [hippocampus](/brain-regions/hippocampus) and [cerebellum](/brain-regions/cerebellum)<sup>[3]</sup>.
See Also
- [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
- [Autophagy-Lysosomal Pathway in Parkinson's](/mechanisms/autophagy-lysosomal-pathway-parkinsons)
- [mTOR Signaling](/mechanisms/mtor-signaling-neurodegeneration)
- [NPC1 Gene](/genes/npc1)
- [LAMP2 Gene](/genes/lamp2)
External Links
- [CTNS - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/1497)
- [CTNS - UniProt](https://www.uniprot.org/uniprot/O60931)
- [Cystinosis - OMIM](https://omim.org/entry/219800)
- [Cystinosis Research Network](https://cystinosis.org/)
References
[Town M et al., A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis (1998) (1998)](https://doi.org/10.1038/ng0698-120)
[Gahl WA et al., Cystinosis (2002) (2002)](https://doi.org/10.1056/NEJMra020552)
[Trauner DA et al., Neurological impairment in nephropathic cystinosis (2010) (2010)](https://doi.org/10.1016/j.jpeds.2009.11.074)
[Kalatzis V et al., Cystinosin, the protein defective in cystinosis, is a H+-driven lysosomal cystine transporter (2001) (2001)](https://doi.org/10.1093/emboj/20.21.5940)
[Ivanova EA et al., Endo-lysosomal dysfunction in human proximal tubular epithelial cells deficient for lysosomal cystine transporter cystinosin (2015) (2015)](https://doi.org/10.1371/journal.pone.0120998)
[Festa BP et al., Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney (2018) (2018)](https://doi.org/10.1038/s41467-018-03853-z)
[Ariceta G et al., Cystinosis in adult and adolescent patients (2015) (2015)](https://doi.org/10.1007/s00467-014-2809-9)
[Syres K et al., Successful treatment of the murine model of cystinosis using bone marrow cell transplantation (2009) (2009)](https://doi.org/10.1182/blood-2009-01-196790)